Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech IPO
Biotech
A new benchmark for biotech IPOs? Kailera raises $625M
Kailera appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its pipeline of obesity therapies.
James Waldron
Apr 17, 2026 4:42am
Did ‘unusually aggressive’ M&A spree trigger March IPO drought?
Apr 15, 2026 9:00am
Kailera plans $528.5 million IPO to support obesity assets
Apr 13, 2026 1:10pm
Seaport, Hemab prepare IPOs to fund depression, clotting drugs
Apr 13, 2026 7:12am
China’s Oricell raises $110M for CAR-T plans ahead of IPO push
Apr 10, 2026 4:11am
Avalyn plans IPO to fund ph. 3 trials of inhaled lung drugs
Apr 9, 2026 4:13am
